December 10, 2019
Financing Will Support Commercialization of Imperative Care’s Stroke Treatments
December 10, 2019—Imperative Care, Inc. announced that it has completed the initial closing of an $85 million Series C financing round to support the commercial launch of the company’s portfolio, which is composed of neurovascular devices to treat ischemic and hemorrhagic strokes.
The company is planning to launch its Large Distal Platform (LDP) access technology and the Zoom aspiration system.
Imperative Care has received FDA 510(k) clearance for its family of access catheters designed to facilitate smooth, consistent navigation into blood vessels of the brain. The FDA has also cleared the Zoom family of products that are designed to facilitate clot removal during ischemic stroke. In addition, Imperative Care continues to develop a pipeline of technology for the continuum of stroke care.
Imperative Care, which is based in Campbell, California, was cofounded in 2016 by neurointerventionist L. Nelson “Nick” Hopkins, MD. Dr. Hopkins is Founder and Chief Scientific Officer of the Jacobs Institute in Buffalo, New York.
Fred Khosravi is Chairman and CEO of Imperative Care, which is the 21st company in 21 years founded by Mr. Khosravi and Incept LLC, a medical technology accelerator.
The financing round was led by new investors Ally Bridge Group and Bain Capital Life Sciences. Also participating in the round were existing Imperative Care investors Ascension Ventures, Delos Capital, Rock Springs Capital, 3H Health Investment, and Incept LLC. Frank Yu, Ally Bridge’s Founder, and Andrew Hack, MD, Managing Director of Bain Capital, will join Imperative Care’s Board of Directors.